

Kathy Oubre MS, Chief Operations Officer, Pontchartrain Cancer Center and Institute Chair

August 21, 2019 • Chicago, IL

AGENDA

8:30 AM • Registration

9:00 AM - 9:15 AM • Welcome: Jim Schwartz RPh NCODA President and Chairman of Executive Council, Texas Oncology

9:15 AM - 10:00 AM • How to Have a Meaningful Relationship with Pharma: Stacey McCullough PharmD, Tennessee Oncology, James Gilmore PharmD, Georgia Cancer Specialists and Kathy Oubre MS, Pontchartrain Cancer Center

Understanding practice's market pressures

Education on non-branded offerings: patient resource books, staff programs; open enrollment, developing an oral adherence program, etc.

Lunch attendance and drop-ins

Use of HUB services: nurse educators, BI, etc.

10:00 AM - 11:00 AM • PBMs and Their Impact on Community Oncology:

Moderator: Ray Bailey RPh, Florida Cancer Specialists, Mike Diaz MD, Florida Cancer Specialists and Kathy Oubre MS, Pontchartrain Cancer Center

Brief history: how PBMs got started and their original purpose

What are they and what do they do?

Impact on healthcare, pharma and consumers

Patient impact stories

Cost avoidance and waste data

11:00 AM - 11:15 AM • Break

11:15 AM - 12:15 PM • Vertical Integration: Thomas Gallo MS, MDA, Virginia Cancer Institute

Explore the factors necessitating change in the US healthcare system

Review innovative healthcare services and care delivery models that are originating in certain geographic markets

Review some of the more important healthcare mergers and alliances occurring on the national scene

Discuss the potential implications that the disruption in the US Healthcare may have on the oncology delivery system

12:15 PM - 1:00 PM • Lunch

1:00 PM - 2:00 PM • USP 800 Impact and Considerations for the Practice:

Moderator: Jonas Congelli RPh, Hematology Oncology Associates of Central New York, Howard Cohen RPh, MS, FASHP, Smilow Cancer Hospital at Yale New Haven Health and Nina Chavez, New Mexico Oncology

Hematology Consultants

Who is USP?

What does this look like financially and operationally for a practice?

What impact will it have on the drugs they represent? And other specialties?

Does the Federal or State level govern this?

2:00 PM - 3:00 PM • Implementing Biosimilars at Your Practice:

Moderator: Ali McBride PharmD, University of Arizona Cancer Center, Kashyap Patel MD, Carolina Blood and Cancer Care and Lisa Raff PharmD, Northwest Oncology & Hematology

What is considered important and not important from a business and operational point of view?

How to operationalize new authorizations

Managing contracts

Kathy Oubre MS, Chief Operations Officer, Pontchartrain Cancer Center and Institute Chair

August 21, 2019 • Chicago, IL

AGENDA

3:00 PM - 3:15 PM • Break

3:15 PM - 4:00 PM • Bills and Legislation Update; How Practices are Getting Involved: Melissa Dillmon MD, Harbin Clinic

4:00 PM - 5:00 PM • Lightning Round: Medicare Step Therapy Rule, Process of Going Beyond the First Fill and Other Current Topics:

Moderator: Kathy Oubre MS, Pontchartrain Cancer Center, Mike Diaz MD, Florida Cancer Specialists, Thomas Gallo MS, MDA, Virginia Cancer Institute and Jan Montgomery PharmD, South Carolina Oncology Associates

5:00 PM • Wrap-Up & Adjourn

5:15 PM • Networking Reception

**All topics and speakers subject to change*